NASH

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, February 21, 2024

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The equity awards were granted as inducement material to the employees’ acceptance of employment with the company.
  • All restricted stock units granted vest in a 25% increment on each of the first through fourth anniversaries of the grant date.
  • The vesting of all awards described above shall be subject to each such employee’s continued employment as of the vesting date.

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Retrieved on: 
Tuesday, February 20, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring Stephen Harrison, MD, Visiting Professor in the Radcliffe Department of Medicine at the University of Oxford, UK, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Aligos’ Phase 2a HERALD study, intended to evaluate the safety and efficacy of ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring Stephen Harrison, MD, Visiting Professor in the Radcliffe Department of Medicine at the University of Oxford, UK, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Aligos’ Phase 2a HERALD study, intended to evaluate the safety and efficacy of ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET.
  • To register, click here.
  • During the event, Dr. Harrison will also discuss some of the key differentiating features of ALG-055009, a next generation thyroid hormone beta agonist.
  • A live question and answer will follow the formal presentation.

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Retrieved on: 
Wednesday, February 28, 2024

(NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”.

Key Points: 
  • (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”.
  • This invention addresses the use of Namodenoson for the reduction of liver fat in patients with NASH a clinical indication that is being developed by Can-Fite.
  • The Company also has a distribution agreement in Canada for its anti-inflammatory drug, Piclidenoson, for the treatment of psoriasis.
  • “This additional patent in Canada for fatty liver disease adds to our growing IP estate for this high-value indication of the Namodenoson drug candidate.

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.

Key Points: 
  • Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.
  • Costs of Captisol sales were $1.6 million for the fourth quarter of 2023, compared with $21.6 million for the same period in 2022, with the decrease due to lower total Captisol sales during the fourth quarter of 2023 and $9.8 million in accelerated depreciation on Captisol manufacturing equipment during the fourth quarter of 2022.
  • Amortization of intangibles was $8.3 million for the fourth quarter of 2023, compared with $8.5 million for the same period in 2022.
  • Travere also announced fourth quarter 2023 results reporting that it received 459 new patient start forms for FILSPARI in the fourth quarter of 2023 and net product sales of $14.9 million for the fourth quarter.

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System

Retrieved on: 
Wednesday, February 21, 2024

The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), is a global coding system used to indicate a diagnosis for reimbursement purposes.

Key Points: 
  • The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), is a global coding system used to indicate a diagnosis for reimbursement purposes.
  • These codes are issued by the World Health Organization (WHO) and are used to show payers why a particular service was medically necessary.
  • The inclusion of NAFLD under the ICD-10 K76.0 code facilitates standardized billing for its diagnosis.
  • "This positive development is testament to the growing awareness of liver health and the intensifying need for effective diagnostic solutions.

NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)

Retrieved on: 
Wednesday, February 21, 2024

The trial is a randomized, double-blind, Phase 2a, placebo-controlled study, which will be conducted at multiple sites across North America.

Key Points: 
  • The trial is a randomized, double-blind, Phase 2a, placebo-controlled study, which will be conducted at multiple sites across North America.
  • It is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Orziloben in adult subjects with IFALD.
  • Commenting on the milestone, Rob de Ree, NST’s CEO, said: "Dosing the first patient in our Phase 2a trial for Orziloben in IFALD is a significant achievement for NorthSea Therapeutics, and is a testament to our commitment to advance innovative treatments for liver diseases.
  • In one pre-clinical model of PN-induced liver injury, Orziloben treatment completely prevented severe cholestasis and the development of fibrosis.

Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

Retrieved on: 
Tuesday, February 20, 2024

Breakthrough status is reserved for technologies that demonstrate the potential to be more effective than current standard of care in patients with serious or life-threatening conditions.

Key Points: 
  • Breakthrough status is reserved for technologies that demonstrate the potential to be more effective than current standard of care in patients with serious or life-threatening conditions.
  • Better Therapeutics earned breakthrough status based on the outcomes of its LivVita clinical study, which successfully met its primary endpoint by reducing liver fat within 90 days, while also achieving key secondary endpoints related to improved liver health without any device-related adverse events.
  • “This also reinforces the potential for our therapeutics platform to broadly address metabolic disorders."
  • Better Therapeutics’ novel form of CBT works by targeting the lifestyle behaviors that are known to cause and/or contribute to the progression of metabolic diseases.

Lindus Health Launches "All-In-One Metabolic CRO" Offering to Accelerate and Enhance Metabolic Clinical Trials

Retrieved on: 
Tuesday, March 5, 2024

This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.

Key Points: 
  • This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.
  • "Our All-in-One Metabolic CRO offering is designed to streamline study activities at every stage of research.
  • Lindus carries a site team with extensive resumes in the metabolic study execution that cover roles across PIs, CRCs, and more.
  • Lindus Health's all-encompassing Metabolic CRO offering empowers metabolic disease sponsors to run more timely and successful clinical trials while enhancing patient experience.

Liaison and NASH Announce Strategic Partnership to Launch Centralized Application Service, Addressing Pressing Challenges in Higher Education

Retrieved on: 
Thursday, February 29, 2024

WATERTOWN, Mass., Feb. 29, 2024 /PRNewswire/ -- Liaison and the National Association of Higher Education Systems (NASH) announce a first-of-its-kind partnership that will accelerate student access and foster success across the United States using Liaison's Centralized Application Service (CAS).  By adopting an application strategy that prioritizes student pathways, the system is designed to streamline enrollment and transfers, significantly reducing administrative burdens and inefficiencies. Functioning as a centralized access point, CAS simplifies the application process, allowing students to apply to multiple campuses and programs within each system using a single application. The partnership brings together NASH's commitment to increasing college attainment rates through systemness and Liaison's technological prowess in data and analytics and higher education expertise.

Key Points: 
  • WATERTOWN, Mass., Feb. 29, 2024 /PRNewswire/ -- Liaison and the National Association of Higher Education Systems (NASH) announce a first-of-its-kind partnership that will accelerate student access and foster success across the United States using Liaison's Centralized Application Service (CAS).
  • The partnership brings together NASH's commitment to increasing college attainment rates through systemness and Liaison's technological prowess in data and analytics and higher education expertise.
  • "The synergy between NASH and Liaison represents a transformative approach to public higher education," said George Haddad, Founder and CEO of Liaison.
  • For more information about this partnership and its impact on the future of education, please visit our partnership page .

National Higher Education Teaching Conference '24 Focuses on Accelerating the Great College Teaching Movement

Retrieved on: 
Thursday, February 29, 2024

NEW YORK, Feb. 29, 2024 /PRNewswire-PRWeb/ -- Today Association of College and University Educators (ACUE) unveiled the stellar line up of higher education leaders and change makers who will present at the second annual National Higher Education Teaching Conference (NHETC). Slated for June 13-14, 2024, at the Hilton Minneapolis, the conference will focus its discussion on helping higher education leaders navigate change to advance great teaching at their institutions.

Key Points: 
  • NEW YORK, Feb. 29, 2024 /PRNewswire-PRWeb/ -- Today Association of College and University Educators (ACUE) unveiled the stellar line up of higher education leaders and change makers who will present at the second annual National Higher Education Teaching Conference (NHETC) .
  • Slated for June 13-14, 2024, at the Hilton Minneapolis, the conference will focus its discussion on helping higher education leaders navigate change to advance great teaching at their institutions.
  • His keynote, "Strategies for Leading Through Change and Uncertainty" will offer insights on how leaders can effectively advance the great teaching movement across higher education, starting within their own campus communities.
  • An inspirational closing plenary will send NHETC '24 attendees back to their colleges and universities ready to grow the great teaching movement.